The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. "I think it could be a potentially ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...